Objective: There is little information on the advantages of nonglucose carbohydrates in total parenteral nutrition (TPN) for diabetic patients. The aim of this study is to evaluate glycemic control and insulin requirements in diabetic patients who received TPN with different sources of carbohydrates, and to determine whether insulin requirements are different when septic and non-septic diabetic patients are studied. Materials and Methods: One-hundred and thirty-eight patients were randomly divided into two groups receiving either glucose (G), n ¼ 71, or glucose-fructose-xylitol 2 : 1 : 1 (GFX), n ¼ 67. There were no differences between the demographic or anthropometric characteristics of the groups, nor between the patients with diabetes mellitus type 1 and type 2, nor the initial TPN composition. Acceptable glycemic control was considered when glycemia reached < 200 mg=dl. Results: Glycemic control was attained in 79.7% of patients (74.6 vs 85.1%), in the same period of treatment. At the end of treatment, insulin requirements were not different (45 AE 19 vs 45 AE 26 UI=day) in both groups, while similar amounts of carbohydrates (191 AE 36 vs 187 AE 45 g=day) were infused. The ratio insulin=body weight and insulin=carbohydrates were equal in both groups. In the GFX group nonseptic and septic patients needed less and more insulin, respectively, than their counterparts in the G group. No major adverse events related to carbohydrate infusions were observed. Conclusions: Either G or GFX could be used in TPN for diabetic patients, providing glycemic control in most cases with similar insulin requirements. GFX mixtures were slightly more beneficial to attain glycemic control in nonseptic patients, but septic diabetic patients had higher insulin needs in this group.
Introduction
Glucose is the most commonly used carbohydrate for total parenteral nutrition (TPN) solutions. Glucose utilization in the fasting state is largely (70%) noninsulin-dependent. However, in the postprandial state, glucose uptake is an insulin-dependent process in adipose and skeletal muscle tissues. There are pathological situations in which glucose utilization is worsened (Van Eys, 1986) . Diabetes mellitus is characterized by absolute (type 1) or relative (type 2) insulin deficiency. Under these conditions, glucose infusion may cause hyperglycemia (McMahon et al, 1989; Valero et al, 1996) . Fructose and xylitol have been used as alternative sources of carbohydrates in intravenous infusions. These sugars are metabolized in the liver via insulin-independent pathways, so their use could decrease the plasma glucose concentration in diabetic patients receiving TPN solutions. Although there are reports in the past on the use of alternative carbohydrates in TPN, there is a lack of specific information about the advantages of nonglucose carbohydrates vs glucose in diabetic patients with or without sepsis. Further, in those reports the amount of these fuels provided was far above that presently considered as acceptable.
The aims of this study were (a) to compare the effects on metabolic control of glucose (G) vs glucose -fructosexylitol mixtures (GFX) given in isocaloric amounts to diabetic patients during TPN infusion, and (b) to study whether insulin requirements were different when septic and nonseptic diabetic patients were considered.
Material and methods
The patients were randomized into two groups: (1) glucose (G), as dextrose solutions (Laboratorio Grifols, Barcelona, Spain), (2) glucose -xylitol -fructose (GFX) 2 : 1 : 1, as Caloplasmal 1 (B Braun, Barcelona, Spain). The patients and investigators were unaware of the patients' solution assignments. The only person aware of the assignments was the research pharmacist, who kept the code sealed until the time of data analysis. Institutional review board approval of the study protocol was obtained.
Entry criteria
Diabetic patients over 18 y of age with digestive intolerance that required TPN were included. Patients were excluded if they showed gastrointestinal tolerance of oral or enteral diets, they had ketoacidosis or nonketotic hyperosmolar coma, or when TPN was required for less than 5 days. None of our patients had a previous history of congenital fructose intolerance.
Demographic characteristics
One-hundred and thirty-eight patients, 68 women and 70 men were studied. Twenty-nine patients (21%) had a previous diagnosis of type 1 diabetes, and 109 (79%) of type 2. Forty-two (38.5%) of these patients were currently treated with diet, 53 (48.6%) with oral antidiabetic agents and 14 (12.8%) with insulin. All the patients were attended by our Nutritional Support Service and they received nothing orally. The indications for nutritional support were elective surgery in 81 cases (58.7%), urgent surgery in 16 (11.6%), gastrointestinal fistula in 12 (8.7%), pancreatitis or pancreatic pseudocysts in 11 (8%), gastrointestinal hemorrhage in four (2.9%) and other diseases in 14 cases (10.1%; Table 1 ). TPN was required by absence of gastrointestinal function or by lack of enteral access.
In the G group, 17 patients were classified as having type 1 diabetes and 54 type 2 (21 treated with diet, 25 with oral antidiabetic agents and eight with insulin). In the GFX group, 12 patients had type 1 diabetes and 55 type 2 (21 treated with diet, 28 with antidiabetic drugs and six with insulin). Seven patients in the G group and six patients in the GFX group had serum creatinine levels above 1.5 mg=dl before TPN infusion.
There were no differences between groups in age, gender, anthropometric characteristics, basal energy expenditure or diabetes type (Table 2) .
General procedures
Total caloric requirements were calculated according to sex, age, height and weight (Harris Benedict formula), as 130 -150% of the basal energy expenditure (5.30 MJ=day, 1268 kcal=day). When the patients were obese, we used an adjusted body weight, by assuming that one-quarter of weight above the ideal or desirable is metabolically active (adjusted W ¼ ((ABW 7 IBW)Â0.25) þ IBW), where ABW is actual body weight and IBW is ideal body weight (Tighe et al, 1993) . The volume of TPN was given as 0.0042 ml=MJ (1 ml=kcal) at a constant rate of infusion, regulated by a volumetric infusion pump, unless volume restriction was indicated.
Individual prescriptions for macronutrients and standard trace elements (10 ml, Pharmacia, Barcelona, Spain) and vitamin solutions (10 ml, Clintec, Madrid, Spain) were provided for all patients. Electrolytes were added as needed. At the start of the treatment, amino acids (Freamine 10%, Pharmacia & Upjohn, Barcelona) were provided at 1.33 AE 0.3 g=kg of weight (87.1 AE 17.2 g=day) as standard amino acids solution, and 0.92 AE 0.17 g=kg (60.6 AE 11.5 g=day) of fat was given as medium-and long-chain triglycerides (20% MCT=LCT 50=50, Lipofundin, B. Braun, Barcelona). TPN was administered as an all-inone mixture.
Seventy-one patients were assigned to receive G, and 67 patients the GFX 2 : 1 : 1 mixture. Patients were initially given 2.86 AE 0.53 g=kg=day of carbohydrates in the G group and 2.89 AE 0.71 g=kg=day in the GFX group. In both groups the patients received similar caloric percentage of carbo-hydrates (44.7 AE 5.1 vs 43.6 AE 6.4%). Capillary glycemia was measured every 6 h. Regular human insulin was provided in the TPN bags. Its infusion rate was regulated on the basis of capillary and serum glucose determinations. There were no differences between groups in composition of macronutrients in the solution at day 1 (Table 3) . Acceptable glycemic control was considered when glycemia was within the 150 -200 mg=dl range. When glucose values were above 200 mg=dl, subcutaneous (s.c.) regular human insulin was administered according to an algorithm. When glucose values were above 200 mg=dl, two-thirds of the s.c. regular human insulin administered over a 24 h period was added to the TPN the following day. If acceptable glycemic control was not met, carbohydrates were reduced in the TPN, and lipids were increased to maintain the caloric content. The administered carbohydrates were increased if the serum glucose levels were consistently below 200 mg=dl. Patients finished the study when they showed gastrointestinal tolerance of oral or enteral diets.
Serum biochemical parameters were evaluated on day 0, then weekly, and on the last day of TPN infusion using an automated technique (Hitachi 717). These determinations included creatinine, glucose, electrolytes and liver function tests.
End points
End points were insulin requirements, number of patients who had glycemia within the 150 -200 mg=dl range, as recommended (McMahon et al, 1989) , and number of days until acceptable glycemic control was reached.
Statistical analysis
Data are expressed as mean AE standard deviation. The difference of means between the two groups was performed with the Student's t-test for variables with a normal distribution or with Wilcoxon matched-pairs signed-ranks test for abnormal distribution. A P-value below 0.05 was considered significant.
Results
TPN solutions were provided for 11.4 days as a mean (median 8 days, range 5 -46 days), until the patients showed gastrointestinal tolerance of oral or enteral diets. On the first day of TPN infusion, 42 patients had glycemia above 200 mg=dl, 24 patients in the G group and 18 in the GFX group.
Acceptable glycemic control was attained at 2.5 AE 1.7 vs 2.4 AE 2.1 days, respectively, since the beginning of TPN. At the end of treatment, glycemia was below 200 mg=dl in 79.7% of patients, when G (74.6%) or GFX (85.1%) was used. Insulin provided in the TPN bag, 45 AE 19 vs 45 AE 26 UI=day, and carbohydrates, 191 AE 36 vs 187 AE 45 g=day, was similar in both groups. The composition of macronutrients on the last day of TPN infusion is shown in Table 4 . There were no differences in daily mean glycemia (Figure 1 ) nor in total daily insulin requirements, considering subcutaneous insulin and insulin in the TPN bag (Figure 2) .
The ratio insulin : body weight (0.69 AE 0.29 vs 0.68 AE 0.41 UI=kg) and insulin : carbohydrates (0.25 AE 0.16 vs 0.31 AE 0.31 UI=g) were similar in the two groups. Insulin requirements were similar between the patients with type 1 diabetes in the G (53 AE 21 UI) and in the GFX group (55 AE 29 UI). Insulin requirements were also similar with type 2 in the G (42 AE 18 UI) and in the GFX group (43 AE 25 UI). There was no differences in insulin needs between type 1 and type 2 diabetic patients in the GFX According to the definition of American College of Chest Physicians=Society of Critical Care Medicine (ACCP=SCCM) Consensus Conference (1992), 26 (18.8%) patients developed severe sepsis during the period of study: 10 patients in the G group (14.1%) and 16 (23.9%) patients in the GFX group. Septic patients in the GFX group received TPN with a slightly higher insulin dose than those in the G group (P ¼ 0.084). However, in nonseptic patients, insulin needs were lower in this group (P ¼ 0.026, Table 5 ). Acceptable glycemic control in septic patients was attained at 2.7 AE 1.9 day in the G group and at 4.2 AE 2.4 day in the GFX group (P ¼ 0.190). However, two patients in one group and seven in the other still had a poor glycemic control on the last day of TPN infusion. On the other hand, there were no differences in insulin requirements in the G group between septic and nonseptic patients (P ¼ 0.359), but higher doses of insulin were administered to septic patients in the GFX group (P < 0.001).
No significant toxicity was seen in our study. Biochemical parameters were similar in both groups of treatment (Table 6 ). Liver function tests were modified during TPN therapy. In both groups there was a significant increase of alkaline phosphatase and GGT. In the GFX group the frequency of elevated bilirubin at day 1 and on the last day was 13.4%, but in the G group these percentages for the two days were 21.1 and 29.6%, respectively. However, the individual subjects included in these percentages were not identical on day 1 and on the last day. In neither group did any of the patients develop hypoglycemia, ketoacidosis or nonketotic hyperosmolar coma during TPN infusion.
Discussion
The main carbohydrate in the bloodstream is glucose. It is the carbohydrate most frequently used in TPN solutions, but there is an absolute or relative defect in glucose metabolism in certain pathological conditions, such as premature newborn, critically ill and diabetic patients (Van Eys, 1986) . In patients with diabetes mellitus the nutrient requirements (Franz et al, 1994) and indications for TPN (ASPEN Board of Directors, 1993) are supposed to be similar to nondiabetic persons. Diabetic patients have insulin deficiency or insulin resistance or a combination of both. When they receive TPN, hyperglycemia may be a common metabolic complication (McMahon et al, 1989) . Glucose infusion should ideally be limited to 3 -4 mg=kg=min (Ziegler & Smith, 1993) and insulin added to the TPN solution as needed (Michael & Sabo, 1989) . On the other hand, while glucose has many physiologic properties, it also has some metabolic disadvantages. When the rate of glucose infusion is increased, there is a higher oxidation of the glucose to CO 2 , with progressively higher respiratory quotients, and increased work of breathing (Askanazi et al, 1982) . Excessive administration of carbohydrates leads to net lipogenesis in liver and adipose tissue, which replaces net fat oxidation (Quigley et al, 1993; Elwyn, 1987) . It is associated with an increase in dietinduced thermogenesis from 6 to 33% (Schutz et al, 1983) . Malnourished patients have much less glycogen deposit, lower diet-induced thermogenesis, and higher lipogenesis than normal subjects (Ziegler & Smith, 1993) .
To avoid or minimize the detrimental effect of the excess of glucose, it must be administered in lower amounts or other carbohydrate sources should be used. Glucose substitutes used in TPN are fructose, glycerol, sorbitol and xylitol. The parenteral infusion of these substrates has been shown to have several advantages: a rapid metabolism, initially independent of insulin, a smaller effect on blood glucose concentration as compared to glucose infusions, an antiketogenic effect and a less damaging effect on veins (Sestoft, 1985) . At the same time, during intravenous infusion of xylitol, glucose and insulin levels remain unchanged (Georgieff et al, 1984) . Xylitol and fructose administration is more rapidly followed by a storage of large amounts of glycogen in the liver, compared with that of glucose (Föer-ster et al, 1972) . This will later reduce the need for gluconeogenesis from amino acids (Hessov, 1985) . As with fructose, in critically ill experimental animals the infusion of xylitol leads to reduced gluconeogenesis, increased protein and muscle RNA content and improved nitrogen balance (Drews et al, 1992; Ardawi, 1992) , but some investigators have failed to show a superiority of xylitol over glucose in rats (Fried et al, 1990) .
In humans, the studies of these carbohydrates in comparison with glucose have usually been performed in healthy volunteers or in critically ill patients, but not in diabetic patients. The main goal of our study was to know more about the advantages of these carbohydrates in diabetic patients with and without sepsis. Lev-Ran et al (1987) compared, in a double-blind randomized study, glycerol and glucose given in isocaloric amounts as addition to amino acids for diabetic patients undergoing selective surgery. The patients treated with glycerol solution required less insulin for the same degree of control of glycemia. These observations have been noted in healthy persons (Tao et al, 1983; Freeman et al, 1983) and in injured patients (Singer et al, 1992) . However, during experimental administration of glycerol, hemolysis and hemoglobinuria, acute renal failure, hepatic fat accumulation and hypertrygliceridemia have been observed (Oken et al, 1966; Marin et al, 1975) especially when glycerol was administered at rates above than 0.74 g=kg=h (García de Lorenzo et al, 1996) .
The mixtures of glucose, fructose and sugar alcohols offer the advantage of providing carbohydrates below their individual dose-limit of utilization and toxicity. The most commonly used combination is glucose, fructose and xylitol in the proportion of 2 : 1 : 1. Plasma glucose levels were significantly higher when glucose was given alone than when given with GFX mixture (Leutenegger et al, 1977; Ladefoged et al, 1982; Ohyanagi, 1994) , but these studies did not include diabetic patients.
In the present study we observed no difference in glycemic control or in insulin requirements between the two solutions in diabetic patients. Metabolic control with serum glucose levels below 200 mg=dl was reached at the same period of treatment with G or GFX. In contrast, Leutenegger et al (1977) showed that the mean daily insulin requirements were significantly greater when glucose alone was given. In our study, insulin requirements were similar with both solutions, but nonseptic patients needed less insulin with GFX than with G solutions to attain similar metabolic control. However, septic diabetic patients treated with GFX mixture required higher insulin doses than nonseptic patients with the same treatment and septic patients treated with G. We think that our disagreement with the findings of Leutenegger et al (1977) could be due to the fact that they administered carbohydrates at doses clearly above present recommendations, and they did not include septic patients. However, some caution should be exercised in evaluating our results; although the statistical differences were very marked, the sample of septic diabetic patients was small. Different toxicities associated with nonglucose carbohydrates have been observed. Xylitol overdose has caused a few cases of deposits of oxalate crystals in the kidney and brain (Evans et al, 1973; Heye et al, 1991) . Administration of large amounts of fructose or xylitol can produce lactic acidosis (Leutenegger et al, 1977; Ladefoged et al, 1982; Danahoe & Powers, 1970) . In our series, as Ladefoged et al (1982) have reported, ketoacidosis did not appear during GFX infusion. It has been reported that infusion of these solutions can elicit an elevation in serum bilirubin (Danahoe & Powers, 1970) . However, our results, in agreement with those of other authors (Leutenegger et al, 1977; Ladefoged et al, 1982) , show that the infusion of glucose alone or in combination with fructose and xylitol has no influence on bilirubin. Liver enzymes increased in the course of both treatments in a similar way. The major risk associated with the use of nonglucose carbohydrates is the occurrence of life-threatening metabolic complications in hereditary fructose intolerance when this sugar is administered. If this disease is suspected, fructose solutions should not be used.
Evaluation of nonglucose carbohydrates MA Valero et al
Pharmacoeconomic issues must also be taken into consideration. The combined sugar solutions are more expensive than glucose alone. In our center, the cost of glucose is 0.138 Euros per 100 g and GFX 0.243 Euros per 100 g of 2 : 1 : 1 mixture.
In conclusion, insulin requirements are similar with TPN based on GFX or G alone in diabetic patients. No major adverse events have been associated with their use in our patients. GFX mixtures could be beneficial to attain glycemic control in nonseptic diabetic patients, although in our series its use in a small sample of septic patients was very disappointing. In consequence, additional studies specifically focused on the potential benefits of alternative carbohydrates in diabetic patients with and without sepsis are required. Glucose is still more widely accepted and cheaper as the carbohydrate substrate in TPN and it should be the first choice until further studies are performed.
